Cornerstone Pharmaceuticals (2)

Executive Summary

Cornerstone Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering metabolic oncology with its lead small-molecule candidate CPI-613 (devimistat). The drug selectively disrupts mitochondrial energy production in cancer cells, aiming to exploit the altered metabolism of tumors. Founded in 2000 and headquartered in Cranbury, New Jersey, the company has advanced devimistat through multiple clinical trials, primarily targeting pancreatic cancer and other solid tumors. Despite being classified as pre-clinical in some databases, the company has reported Phase 2 data and is likely preparing for Phase 3 registration trials. Its private status limits public visibility, but the metabolic oncology approach offers a differentiated mechanism that could address significant unmet needs, particularly in treatment-resistant cancers.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Top-Line Results for CPI-613 in Pancreatic Cancer40% success
• Q3 2026Strategic Partnership or Licensing Agreement50% success
• Q2 2026FDA Orphan Drug Designation Update or Breakthrough Therapy Status60% success